Charles River Laboratories International, Inc. Common Stock (CRL)
138.79
-2.57 (-1.82%)
NYSE · Last Trade: May 11th, 9:45 AM EDT
The review aims to enhance shareholder value, with four new independent directors joining the board. Despite a 2.7% drop in Q1 revenue, analysts raised their outlook, boosting retail sentiment.
Via Stocktwits · May 7, 2025
Curious about the top performers within the S&P500 index one hour before the close of the markets on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via Chartmill · May 7, 2025
Shares of lab services company Charles River Laboratories (NYSE:CRL)
jumped 17.3% in the afternoon session after the company reported strong first quarter 2025 results which significantly beat analysts' organic revenue and EPS estimates, and featured a raise to full-year EPS guidance. Zooming out, we think this was a solid print.
Via StockStory · May 7, 2025
Let's have a look at the S&P500 stocks with an unusual volume in today's session.
Via Chartmill · May 7, 2025
Charles River shares rise after Q1 adjusted EPS and revenue top estimates; company raises 2025 outlook and adds four directors to its board.
Via Benzinga · May 7, 2025
Stay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.
Via Chartmill · May 7, 2025
Via Benzinga · May 7, 2025
Lab services company Charles River Laboratories (NYSE:CRL) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 2.7% year on year to $984.2 million. Its non-GAAP profit of $2.34 per share was 12.8% above analysts’ consensus estimates.
Via StockStory · May 7, 2025
As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.
Via Chartmill · May 7, 2025
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.
Via Chartmill · May 7, 2025
Via Benzinga · May 7, 2025
Lab services company Charles River Laboratories (NYSE:CRL)
will be announcing earnings results tomorrow before the bell. Here’s what to expect.
Via StockStory · May 6, 2025
Via Benzinga · May 2, 2025
Medical stocks are usually considered defensive. But have they been too hammered by regulatory changes to hold up this year?
Via Investor's Business Daily · May 1, 2025
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months.
Via Talk Markets · April 24, 2025
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months.
Via Talk Markets · April 19, 2025
Amid market turbulence and policy shifts, do two of the S&P 500’s steepest decliners, DECK and CRL, offer deep value or signal deeper trouble ahead?
Via MarketBeat · April 16, 2025
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday.
Via Chartmill · April 14, 2025
Wall Street pared early morning gains by midday Monday, as investor caution returned despite a temporary easing in U.S.-China trade tensions. While the initial market reaction was positive, especially in tech, enthusiasm faded as the trading session progressed.
Via Benzinga · April 14, 2025
FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods.
Via Benzinga · April 14, 2025
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.
Via Chartmill · April 11, 2025